Point72 Asset Management
CTMX icon

Point72 Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Point72 Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37M Buy
7,875,390
+2,685,852
+52% +$13.6M 0.05% 502
2025
Q4 		$22.1M Buy
5,189,538
+1,120,963
+28% +$4.26M 0.02% 818
2025
Q3 		$13M Sell
4,068,575
-4,016,048
-50% -$9.04M 0.02% 703
2025
Q2 		$18.4M Buy
8,084,623
+5,434,623
+205% +$8.76M 0.04% 533
2025
Q1 		$1.68M Hold
2,650,000
– – ﹤0.01% 1291
2024
Q4 		$2.73M Buy
+2,650,000
New +$2.85M 0.01% 1143
2022
Q3 		– Sell
-2,750,000
Closed -$5.03M – 1451
2022
Q2 		$5.03M Sell
2,750,000
-1,621,300
-37% -$3.1M 0.02% 703
2022
Q1 		$11.7M Sell
4,371,300
-1,931,725
-31% -$7.42M 0.05% 468
2021
Q4 		$27.3M Hold
6,303,025
– – 0.11% 272
2021
Q3 		$32.1M Sell
6,303,025
-90,875
-1% -$486K 0.14% 194
2021
Q2 		$40.5M Buy
6,393,900
+58,900
+0.9% +$459K 0.18% 148
2021
Q1 		$49M Buy
6,335,000
+6,210,000
+4,968% +$49.2M 0.23% 111
2020
Q4 		$819K Buy
+125,000
New +$893K ﹤0.01% 823
2020
Q3 		– Sell
-1,033,406
Closed -$8.61M – 955
2020
Q2 		$8.61M Buy
1,033,406
+816,842
+377% +$7.59M 0.06% 372
2020
Q1 		$1.66M Sell
216,564
-504,436
-70% -$3.52M 0.01% 524
2019
Q4 		$5.99M Buy
+721,000
New +$4.86M 0.03% 471
2019
Q3 		– Sell
-330,498
Closed -$3.71M – 1187
2019
Q2 		$3.71M Sell
330,498
-295,151
-47% -$3.09M 0.02% 567
2019
Q1 		$6.73M Sell
625,649
-838,147
-57% -$12.4M 0.03% 495
2018
Q4 		$22.1M Buy
1,463,796
+136,056
+10% +$2.02M 0.11% 237
2018
Q3 		$24.6M Buy
1,327,740
+1,169,569
+739% +$26.6M 0.1% 250
2018
Q2 		$3.62M Buy
+158,171
New +$4.04M 0.01% 672

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Point72 Asset Management's CTMX Position: Q1 2026 in Review

Point72 Asset Management increased its CytomX Therapeutics (CTMX) stake by 52% in Q1 2026, buying an estimated $13.6M and bringing the position to 7,875,390 shares worth $37M. The position accounts for 0.05% of the portfolio, ranked #502.

Point72 Asset Management first reported a position in CTMX in Q2 2018 and has held it in 21 quarters since. The position peaked at $49M in Q1 2021. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Point72 Asset Management held 7,875,390 shares of CytomX Therapeutics worth $37M as of Q1 2026.
  • Point72 Asset Management bought 2,685,852 CytomX Therapeutics shares in Q1 2026, an estimated $13.6M.
  • CytomX Therapeutics made up 0.05% of Point72 Asset Management's portfolio in Q1 2026, its #502 holding.
  • Point72 Asset Management first reported a position in CytomX Therapeutics in Q2 2018 and has held it in 21 quarters since.
  • Point72 Asset Management's CytomX Therapeutics position peaked at $49M in Q1 2021.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.